Please assess the completion status of the following clinical trial:

Trial Title: Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants in previous Phase 1 or 2 trials of ACH-126,443 who met entry criteria for previous studies.~* Adults ? 18 years of age~* Chronic HBV infection, known to be HbsAg positive ? 6 months~* Plasma HBV DNA level ? 100,000 copies/mL prior to initiation of ACH-126,443 in an earlier study~* Plasma HBV DNA level that in the medical judgment of the investigator, warrant's antiviral treatment~* HIV negative~* Basic hematologic and chemistry parameters within acceptable limits (defined in protocol)~* No need for excluded medications~* Subjects of reproductive capability must either practice abstinence or utilize two approved forms of birth control, one of which must be barrier protection (condom with spermicidal, diaphragm with spermicidal)~Exclusion Criteria~* HIV infection~* Active Hepatitis C co-infection~* Concurrent systemic antiviral treatment~* Treatment for HBV infection with lamivudine (3TC) for longer than three (3) months since participation in previous trial of ACH-126,443~* Previous therapy with agents with significant systemic myelosuppressive or cytotoxic potential within 3 months of study start or the expected need for such therapy at study start~* Alcohol abuse~* Pregnancy or breast-feeding~* Inability to tolerate oral medication~* AST\>10.0 times the upper limit of normal~* ALT\>10.0 times the upper limit of normal~* Any clinical condition or prior therapy that, in the Investigators opinion, would make the subject unsuitable for the study or unable to comply with the dosing requirements~* Use of investigational drug not approved by Medical Monitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).